A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Phase 2 – studying effectiveness and dosage
Conditions:
Myasthenia Gravis, Generalized
Sponsor: Vertex Pharmaceuticals Incorporated
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Who can participate
Key Inclusion Criteria:
* Age 18-80 years
* Diagnosis of generalized myasthenia gravis with generalized muscle weakness and fitting MGFA clinical classification II-IV
* Additional inclusion criteria are defined in the protocol
Key Exclusion Criteria:
* History of thymic surgery within 6 months of screening
* History of malignancy within the last 5 years
* Additional exclusion criteria are defined in the protocol
Other protocol defined Inclusion/Exclusion criteria will apply.
БГ